Overview

SNAP-8 (acetyl octapeptide-3) is a synthetic acetylated octapeptide developed by Lipotec as an extension of the hexapeptide Argireline (acetyl hexapeptide-3). Both molecules are inspired by the N-terminal domain of SNAP-25, a component of the SNARE complex that mediates vesicular release of acetylcholine at the neuromuscular junction. SNAP-8 was designed to compete with SNAP-25 for incorporation into the SNARE complex and, in cosmetic use, to modulate the strength of muscle contractions that drive expression-line formation in the upper face.

Unlike almost every other compound in this reference, SNAP-8 is used topically in cosmetic formulations, not by injection. There is no established injectable use in the research literature, and the compound’s clinical evidence base consists primarily of manufacturer-sponsored studies of topical anti-wrinkle formulations rather than independent peer-reviewed trials. Direct clinical data on SNAP-8 specifically is limited; most of the mechanistic rationale is extrapolated from work on the related Argireline hexapeptide.

Mechanism (as reported in the literature)

  • SNARE-complex competition. SNAP-25’s N-terminal domain interacts with syntaxin and VAMP to form the SNARE complex that mediates acetylcholine release at the neuromuscular junction. Peptide fragments modelled on this domain (Argireline; SNAP-8) are reported to competitively bind these partners in vitro, reducing the efficiency of vesicular release.
  • Proposed downstream effect. In topical cosmetic use, this mechanism is proposed to reduce the peak amplitude of expression-line muscle contractions in the treated area, indirectly softening dynamic lines over sustained application intervals.
  • Barrier-permeability caveat. The intact stratum corneum is a substantial barrier to peptides of this size. Manufacturer materials describe formulation systems (liposomal delivery, penetration enhancers) intended to improve dermal delivery, but transdermal delivery of peptides remains an open question in the peer-reviewed literature.
  • No neuromuscular systemic effect reported. No published data suggest that topical SNAP-8 produces the systemic neuromuscular effects associated with clostridial neurotoxins; mechanism-based comparisons with those agents are framed only at the local, in-vitro level.

Research findings

  • Argireline foundational work (Blanes-Mira et al., 2002). The parent hexapeptide Argireline was characterised as competing with SNAP-25 for SNARE-complex assembly in a synaptosomal preparation, with a topical formulation reducing wrinkle depth in a small human study. Published in the International Journal of Cosmetic Science, 2002; 24(5), 303–310.
  • Manufacturer studies of SNAP-8. Sponsor-provided data (Lipotec) reported reductions in wrinkle depth in the peri-orbital region over 28-day topical-application intervals in small volunteer studies. These studies have limited independent peer-reviewed replication.
  • Comparative work with acetyl hexapeptides. Later in-vitro comparisons of Argireline and SNAP-8 reported broadly similar effects on the SNARE-complex assay, with SNAP-8 described as marginally more potent in the assay conditions used.
  • Absence of injectable-use literature. The published literature does not describe injectable use of SNAP-8, and no clinical trials of injectable SNAP-8 in dermatologic indications have been identified.

Common dosing (from published research protocols)

Reported use is in topical cosmetic formulations at concentrations of roughly 0.05% to 1% of the acetyl octapeptide-3 by weight in the finished product. Translating that to a per-application mass is inherently rough — a typical facial application of a few grams of formulation at 0.1% delivers on the order of 1,000 to 10,000 mcg of peptide to the skin surface, of which only a small fraction is expected to cross the stratum corneum. The typical_dose_range_mcg field on this page reflects that topical delivery envelope rather than an injection dose.

Reconstitution

SNAP-8 supplied as a lyophilised research powder can be reconstituted in water for cosmetic formulation work. Because the peptide is not injected, “reconstitution” in the injection sense used elsewhere on this site does not directly apply — the more relevant preparation step is incorporation into a topical vehicle such as a serum or cream base, in a formulation that stabilises the peptide against oxidation of the methionine residue.

Storage

Lyophilised SNAP-8 is reported as stable at refrigerated temperatures. Once dissolved in an aqueous vehicle, storage at 2–8 °C with protection from light is described in cosmetic-industry technical literature, with methionine oxidation being the primary degradation concern.

  • GHK-Cu — a well-characterised copper-binding tripeptide widely used in topical dermatologic formulations.
  • KPV — a tripeptide with topical anti-inflammatory research applications in skin research.
  • Melanotan II — a tangentially related dermatologic peptide with a very different mechanism and route.

Common stacks

References

  • Blanes-Mira, C., et al. (2002). “A synthetic hexapeptide (Argireline) with antiwrinkle activity.” International Journal of Cosmetic Science, 24(5), 303–310.
  • Wang, Y., et al. (2013). “The anti-wrinkle efficacy of Argireline, a synthetic hexapeptide, in Chinese subjects.” American Journal of Clinical Dermatology, 14(2).
  • Lipotec (manufacturer). Technical information on SNAP-8 (acetyl octapeptide-3): mechanism, formulation, and efficacy studies.